ABBOTT-CLOPIDOGREL TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

CLOPIDOGREL (CLOPIDOGREL BISULFATE)

Disponible depuis:

ABBOTT LABORATORIES, LIMITED

Code ATC:

B01AC04

DCI (Dénomination commune internationale):

CLOPIDOGREL

Dosage:

75MG

forme pharmaceutique:

TABLET

Composition:

CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75MG

Mode d'administration:

ORAL

Unités en paquet:

100/500

Type d'ordonnance:

Prescription

Domaine thérapeutique:

PLATELET AGGREGATION INHIBITORS

Descriptif du produit:

Active ingredient group (AIG) number: 0134440001; AHFS:

Statut de autorisation:

CANCELLED POST MARKET

Date de l'autorisation:

2015-12-31

Résumé des caractéristiques du produit

_ _
_Abbott-Clopidogrel Product Monograph _
_Page 1 of 52 _
_ _
_ _
PRODUCT MONOGRAPH
PR
ABBOTT-CLOPIDOGREL
Clopidogrel Tablets USP
75 mg clopidogrel, as clopidogrel bisulfate
Platelet Aggregation Inhibitor
Abbott Laboratories, Limited
8401 Trans-Canada Highway
Saint-Laurent, Quebec
H4S 1Z1
Date of Revision:
November 27, 2014
Submission Control No.: 179756
_ _
_Abbott-Clopidogrel Product Monograph _
_Page 2 of 52 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................24
SPECIAL HANDLING INSTRUCTIONS
.......................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
.........................................................